AUSTIN, Texas--(BUSINESS WIRE)--Acessa Health Inc., developer of the Acessa System®, announced today that its laparoscopic radiofrequency ablation technology was featured at the 47th American Association of Gynecologic Laparoscopists (AAGL) Global Congress on Minimally Invasive Gynecologic Surgery (MIGS).
Presented by Abe Shashoua, MD, this retrospective cohort study looked at all cases of Acessa performed at Advocate Illinois Masonic Medical Center from July 1, 2013 through June 30, 2016 and compared them to all excisional removal of fibroids (myomectomy) performed during this same time to compare outcomes.
“We are excited by the consistent and significant outcomes that we have observed and documented with the Acessa system,” said Dr. Abe Shashoua, Director of Minimally Invasive and Robotic Gynecologic Surgery at Advocate Illinois Masonic Medical Center. “This observational study continues to build upon the strong evidence demonstrating the consistent outcomes associated with the treatment of uterine fibroids with laparoscopic radiofrequency ablation.”
The prospective cohort study collected outcomes data on 112 Acessa procedures and 637 myomectomies that were performed during the study period. Acessa showed similar results in terms of complications, readmissions and subsequent pregnancies. The authors noted that radiofrequency ablation was successfully used and when compared to standard myomectomy that can be employed hysteroscopically, laparoscopically or via laparotomy, Acessa appears to be a safer and more efficient method of treatment of uterine fibroids with respect to the complications one might expect with the traditional methods that have been used in the past.
The Acessa System is the first FDA approved laparoscopic radiofrequency ablation for uterine fibroids and to date utilized in nearly 3,000 procedures. The procedure has been the focus of 29 peer-reviewed clinical publications, which include two systematic reviews with meta-analysis and the third-generation system, Acessa ProVuTM, was recently cleared by the FDA.
“The 2018 AAGL Conference marks an exciting moment for the Acessa ProcedureTM, as this technology continues to demonstrate significant improvement over move invasive surgical options,” said Ryan M. Graver, Senior Vice President of Market Access for Access Health Inc. “This real world study of over 700 patients builds on the strong clinical evidence supporting the overwhelming benefit of laparoscopic radiofrequency ablation for uterine fibroids.”
Studies have noted that women increasingly desire less invasive options. Regarding fibroids, women want to retain their uterus, recover quickly, and avoid inpatient surgery. Unlike many alternative interventions, Acessa can treat almost all sizes and locations of fibroids – including those outside the uterine cavity and within uterine walls. The procedure requires no cutting or suturing of uterine tissue, and patients typically go home the same day, experiencing minimal discomfort and a rapid return to normal activities.
About Acessa Health Inc.
Acessa Health is a women’s health innovator dedicated to advancing minimally invasive, uterine-sparing solutions for women with symptomatic fibroids. The company introduced the use of radiofrequency ablation for the treatment of uterine fibroids and is continuing to develop technologies that improve the lives of its patients. Acessa Health’s headquarters are in Austin, Texas. For more information, visit AcessaProcedure.com.